Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Blood (2025) 146 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2025-3391

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

Blood (2025) 146 (Supplement 1): 5182.

https://doi.org/10.1182/blood-2025-5182

Published: 2025

Journal Articles

Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival

Yanping Sun, Fei Lu, Jingjing Ye, Chunyan Ji

Blood (2025) 146 (Supplement 1): 6307.

https://doi.org/10.1182/blood-2025-6307

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Distinct distributions of lymphocyte subsets in myelodysplastic syndrome correlate with risk stratification

Xiaolin Zhang, Xiran Hou, Guosheng Li, Qiang Song, Ming Hou, Chunyan Ji, Xinguang Liu

Blood (2025) 146 (Supplement 1): 7361.

https://doi.org/10.1182/blood-2025-7361

Published: 2025

Journal Articles

Inhibition of FSP1 enhances venetoclax induced cell death in Acute Myeloid Leukemia by the ferroptosis pathway

Yiping Hao, Wei Li, Min Ji, Jingjing Ye, Chunyan Ji

Blood (2025) 146 (Supplement 1): 6797.

https://doi.org/10.1182/blood-2025-6797

Published: 2025

Journal Articles

A single-center retrospective study of golidocitinib for the treatment of peripheral T-cell lymphoma

Boya Li, Fei Lu, Jingjing Ye, Chunyan Ji

Blood (2025) 146 (Supplement 1): 7166.

https://doi.org/10.1182/blood-2025-7166

Published: 2025

Journal Articles

Impact of central nervous system prophylaxis on survival outcomes in patients with primary testicular diffuse large B-cell lymphoma: A single-center analysis

Qirui Zhou, Jinlin Chen, Yihua Pang, Fei Lu, Jingjing Ye, Chunyan Ji

Blood (2025) 146 (Supplement 1): 7187.

https://doi.org/10.1182/blood-2025-7187

Published: 2025

Journal Articles

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

Blood (2025) 146 (Supplement 1): 7005.

https://doi.org/10.1182/blood-2025-7005

Published: 2025

Journal Articles

The potential factors associated with treatment outcomes in newly diagnosed elderly AML patients treated with first-line venaza therapy: A retrospective study

Gaoyu Lv, Junjie Xu, Wei Zhichen, Xianlei Zhang, Chunyan Ji, Yan Shi

Blood (2025) 146 (Supplement 1): 6927.

https://doi.org/10.1182/blood-2025-6927

Published: 2025

Journal Articles

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Blood (2025) 146 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2025-5205

Published: 2025

Journal Articles

Immunotherapy without or with low-intensity chemotherapy versus standard chemotherapy as first-line treatment for newly diagnosed b-ALL patients: A propensity score-matched study

Bingqian Huang, Yawen Wang, Yubin Li, Jiahui Mao, Ruixue Wang, Chunyan Ji, Yu Hou, Yan Shi, Ming Hou

Blood (2025) 146 (Supplement 1): 6870.

https://doi.org/10.1182/blood-2025-6870

Published: 2025

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

Zinc Oxide Nanoparticles Induce Diffuse Large B-Cell Lymphoma Cell Apoptosis Via Regulating Mitochondrial Dynamics

Zonghong Li, Lili Feng, Chunyan Ji, Ruirong Xu

Blood (2024) 144 (Supplement 1): 5751.

https://doi.org/10.1182/blood-2024-203463

Published: 2024

Journal Articles

Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study

Jie Zou, Xiaoning Yu, Xiaoxia Chu, Ji Ma, Zengjun Li, Chunyan Chen, Yan Liu, Jian Xing, Zhongliang Sun, Chunyan Ji, Jie Li

Blood (2024) 144 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2024-207021

Published: 2024

Journal Articles

High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Blood (2024) 144 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2024-199412

Published: 2024

Journal Articles

Venetoclax Plus Idarubicin and Cytarabine Chemotherapy As First-Line Treatment for Adults with Acute Myeloid Leukaemia

Shaolei Zang, Min Ji, Jingru Zhang, Fei Lu, Chunqing Zhang, Jingjing Ye, Chunyan Ji

Blood (2024) 144 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2024-207613

Published: 2024

Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2023-180694

Published: 2023

Journal Articles

Adiponectin Promote TPO Response for Treating ITP By Relating Rab6A-myosin9 Trafficking Vehicle Carrying c-Mpl to Cell Surface

Xin Zhao, Huixian Ma, Guosheng Li, Tao Sun, Chunyan Ji

Blood (2023) 142 (Supplement 1): 5398.

https://doi.org/10.1182/blood-2023-185592

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Distinct distributions of lymphocyte subsets in myelodysplastic syndrome correlate with risk stratification

Inhibition of FSP1 enhances venetoclax induced cell death in Acute Myeloid Leukemia by the ferroptosis pathway

A single-center retrospective study of golidocitinib for the treatment of peripheral T-cell lymphoma

Impact of central nervous system prophylaxis on survival outcomes in patients with primary testicular diffuse large B-cell lymphoma: A single-center analysis

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

The potential factors associated with treatment outcomes in newly diagnosed elderly AML patients treated with first-line venaza therapy: A retrospective study

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Immunotherapy without or with low-intensity chemotherapy versus standard chemotherapy as first-line treatment for newly diagnosed b-ALL patients: A propensity score-matched study

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Zinc Oxide Nanoparticles Induce Diffuse Large B-Cell Lymphoma Cell Apoptosis Via Regulating Mitochondrial Dynamics

Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study

High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Venetoclax Plus Idarubicin and Cytarabine Chemotherapy As First-Line Treatment for Adults with Acute Myeloid Leukaemia

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Adiponectin Promote TPO Response for Treating ITP By Relating Rab6A-myosin9 Trafficking Vehicle Carrying c-Mpl to Cell Surface

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only